AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AMPLIA THERAPEUTICS LTD

0.150

0.000

Volume:707.96K

Turnover:105.96K

Market Cap:76.96M

PE:-9.15

High:0.150

Open:0.150

Low:0.145

Close:0.150

52wk High:0.275

52wk Low:0.100

Shares:513.07M

Float Shares:351.32M

Volume Ratio:2.28

T/O Rate:0.20%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.016

EPS(LYR):-0.016

ROE:-25.48%

ROA:-16.29%

PB:1.95

PE(LYR):-9.15

Loading ...

Overview Company News Filings

Amplia Therapeutics Signs Trial Collaboration with Lilly for Narmafotinib-Olomorasib NSCLC Study

Amplia Signs Collaboration Agreement with Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12c Inhibitor, Olomorasib, in Non-Small Cell Lung Cancer

THOMSON REUTERS

Amplia Therapeutics to Evaluate Combination Therapy for Non-Small Cell Lung Cancer in Collaboration With Eli Lilly

MT Newswires Live

Amplia Therapeutics - to Begin Study in Late 2026 in Australia and USA

THOMSON REUTERS

Amplia Therapeutics - and Lilly to Evaluate Narmafotinib and Olomorasib Combination

THOMSON REUTERS

Amplia Therapeutics Ltd-Amplia Signs Collaboration and Supply Agreement with Lilly

THOMSON REUTERS

Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer NOW Online

THOMSON REUTERS

Amplia Announces Appointment of Brett Carter to Board

THOMSON REUTERS

Amplia Therapeutics Names Jane Bell Chair as Warwick Tong Steps Down

Amplia Therapeutics Says Warwick Tong Will Retire as Board Chairman

Amplia Therapeutics Says Warwick Tong Will Retire as Board Chairman

Amplia Therapeutics Ltd - Warwick Tong Will Retire as Board Chairman

THOMSON REUTERS

Amplia Therapeutics - Appoints Jane Bell am as Board Chair Effective 30 June 2026

THOMSON REUTERS

Amplia Therapeutics Says Washington H. Soul Pattinson Becomes Substantial Holder

MT Newswires Live

Amplia Therapeutics Says Pengana Capital Becomes Substantial Holder

MT Newswires Live

Amplia Therapeutics - Loss for Year Attributable a$7.7 Mln

THOMSON REUTERS

Amplia Therapeutics Ltd - FY REV and Other Income a$5.5 Mln

THOMSON REUTERS

Amplia Therapeutics to Start Phase 2B Study of Pancreatic Cancer Drug Candidate

MT Newswires Live

Amplia Therapeutics launches Phase 2b narmafotinib trial in advanced pancreatic cancer

Amplia Therapeutics issues 240,385 shares on CMO option exercise under equity plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ATX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ATX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","market":"AU","secType":"STK","nameCN":"AMPLIA THERAPEUTICS LTD","latestPrice":0.15,"timestamp":1787292720000,"preClose":0.15,"halted":0,"volume":707959,"delay":0,"changeRate":0,"nameEN":"AMPLIA THERAPEUTICS LTD","floatShares":351321835,"shares":513071629,"eps":-0.0164,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-21 16:12:00 AEST","open":0.15,"high":0.15,"low":0.145,"amount":105964,"amplitude":0.033333,"askPrice":0.15,"askSize":463434,"bidPrice":0.145,"bidSize":277530,"shortable":3,"etf":0,"ttmEps":-0.0164,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.15,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":2.2828123285284554,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ATX.AU","preClose":0.15,"auctionPrice":0.15,"auctionVolume":93761,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600773}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","floatShares":351321835,"roa":"-16.29%","roe":"-25.48%","lyrEps":-0.0164,"volumeRatio":2.2828123285284554,"shares":513071629,"dividePrice":0,"high":0.15,"amplitude":0.033333,"preClose":0.15,"low":0.145,"week52Low":0.1,"pbRate":"1.95","psRate":"16.06","week52High":0.275,"institutionHeld":0,"latestPrice":0.15,"committee":-0.250895,"eps":-0.0164,"divideRate":0,"volume":707959,"delay":0,"ttmEps":-0.0164,"open":0.15,"prevYearClose":0.15,"prevWeekClose":0.145,"prevMonthClose":0.13,"prevQuarterClose":0.145,"fiveDayClose":0.145,"twentyDayClose":0.14,"sixtyDayClose":0.135,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATX.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-04-18","symbol":"ATX.AU","defaultRemindTime":1713398400000,"type":"split","dateTimestamp":1713362400000,"forFactor":971896,"toFactor":1000000,"ratio":0.971896}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656567235","title":"Amplia Therapeutics Signs Trial Collaboration with Lilly for Narmafotinib-Olomorasib NSCLC Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2656567235","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656567235?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:45","pubTimestamp":1785847551,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics signs trial collaboration with Lilly for narmafotinib-olomorasib NSCLC studyAmplia entered a clinical trial collaboration and supply agreement with Eli Lilly to test narmafotinib w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL4rKcYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","BK7067","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD","BK4585","ATX.AU","IE00BN0W2W23.USD","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","IE00B3QW5Z07.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656794556","title":"Amplia Signs Collaboration Agreement with Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12c Inhibitor, Olomorasib, in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656794556","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656794556?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:45","pubTimestamp":1785847500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA96JSHB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656588824","title":"Amplia Therapeutics to Evaluate Combination Therapy for Non-Small Cell Lung Cancer in Collaboration With Eli Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=2656588824","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656588824?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:23","pubTimestamp":1785799418,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  struck a collaboration and supply agreement with US-listed pharmaceutical giant Eli Lilly to evaluate an investigational drug combination as a second-line treatment for patients with advanced-stage non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.As part of the deal, a phase 1b/2b clinical trial will assess the safety and efficacy of Amplia's narmafotinib in combination with Eli Lilly's olomorasib, per the filing.Amplia will conduct the trial, which is planned to launch late this year, at sites in Australia and the US. The companies will collaborate to finalize the clinical study protocol and other associated documents.The study extends narmafotinib's clinical development from pancreatic cancer into non-small cell lung cancer, for which the market is currently valued at about $31 billion, Amplia said. It added that narmafotinib showed a range of \"compelling efficacy signals\" across responses and survival in a previous study, with","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999014914.USD","LU2089283258.USD","SG9999014880.SGD","IE0001KFT4U8.USD","BK4534","IE00B2B36J28.USD","LU0823434583.USD","LU2360106947.USD","LU1551013425.SGD","LU2106854487.HKD","LU1712237335.SGD","SG9999001176.USD","ILDR","LU2168564065.EUR","IE00BKDWB100.SGD","LLYZ","LU2237443549.SGD","LU2237443622.USD","LU2237443895.HKD","LU2265009873.SGD","LU2271345857.HKD","MEDI","LU0353189680.USD","LU0823434740.USD","LU0820561818.USD","LU2237438978.USD","ELIL","IE00BN29S564.USD","LLY","IE00B7KXQ091.USD","LU1232071149.USD","LU0683600562.USD","LU2237443978.SGD","LU0256863902.USD","LU0823416689.USD","LU0203201768.USD","BK4599","LU1983299246.USD","IE00BJJMRZ35.SGD","LU2361044865.SGD","LU0323591593.USD","LU1548497426.USD","LU0889565916.HKD","SG9999013999.USD","LU1623119135.USD","LU1979441026.SGD","GB00BDT5M118.USD","SG9999018865.SGD","LU0109394709.USD","LU0466842654.USD","LU2750360997.AUD","LU2087625088.SGD","AGNG","CURE","LU0097036916.USD","LU0006306889.USD","LU0432979614.USD","LU1127390331.HKD","SGXZ81514606.USD","LU2023250504.SGD","BK4581","LU0354030511.USD","LU1291159041.SGD","LU2089984988.USD","LLII","LU0133085943.USD","LU0786609619.USD","LU0238689110.USD","IE0005OL40V9.USD","LU2168564222.USD","IE00BK4W5M84.HKD","LU2112291526.USD","LU0158827781.USD","LU2264538146.SGD","LU0316494557.USD","LU2324357040.USD","LU0096364046.USD","LU1868837300.USD","SGXZ31699556.SGD","SGXZ51526630.SGD","LU2168563687.JPY","IE00B1BXHZ80.USD","LLYX","IE00BFTCPJ56.SGD","LU1868837136.USD","SG9999015952.SGD","LU0672654240.SGD","IE00B4JS1V06.HKD","LU1974910355.USD","BK4516","LU2361044949.HKD","LU2168564495.EUR","IE00BK4W5L77.USD","LU2237443382.USD","LU2237443465.HKD","MHIP","LU2468319806.SGD","LU0345770308.USD","LU2417539215.USD","LU2896262040.SGD","LU0114720955.EUR","IE00BKPKM429.USD","LU1145028129.USD","LU2236285917.USD","LU0256863811.USD","ELIS","LU1057294990.SGD","LU2213496289.HKD","CANC","LU1093756168.USD","LU2491049909.HKD","LU2023251221.USD","LU1917777945.USD","LU2750360641.GBP","VHT","WDNA","LU1720051108.HKD","LU2491050071.SGD","LU1280957306.USD","LU2552382215.SGD","LU1035775433.USD","LU2108987350.USD","LU2462157665.USD","LU0820562030.AUD","LU0094547139.USD","LU1267930730.SGD","LU0471298694.HKD","LU1023059063.AUD","IXJ","LU0689472784.USD","PJP","LU2471134796.USD","LU0345770993.USD","LU2089284900.SGD","IE00B775H168.HKD","LU2028103732.USD","BK4588","LU2471134952.CNY","LU1069344957.HKD","LU0943347566.SGD","IE00BFSS7M15.SGD","LU2602419157.SGD","LU0158827948.USD","LU1868836591.USD","IE00BJJMRX11.SGD","LU1868836757.USD","RXL","LU2357305700.SGD","LU1093756325.SGD","LU1366192091.USD","LU2471134523.USD","FTXH","SG9999017495.SGD","LU0122379950.USD","TRUH","HRTS","LU2756315318.SGD","LU0882574139.USD","LU0289739699.SGD","SGXZ99366536.SGD","IE00B1XK9C88.USD","LU2063271972.USD","XLV","THNR","BK4007","LU1629891620.HKD","LU0820561909.HKD","SG9999015986.USD","IE00BWXC8680.SGD","LU0354030438.USD","ATX.AU","LU0417517546.SGD","IE0004445239.USD","BK4533","IE00BFSS8Q28.SGD","LU0708995401.HKD","LU1720051017.SGD","LU2111349929.HKD","LU2361045086.USD","LU0456855351.SGD","LU1814569148.SGD","LU2023250330.USD","LU2211815571.USD","LU2746668974.SGD","JDOC","TMED","LU0787776722.HKD","IE0002141913.USD","BK7067","LU2456880835.USD","LU2462591350.SGD","LU2461242641.AUD","IYH","LU0198837287.USD","LU2756315664.SGD","IE00BJJMRY28.SGD","LU1064131342.USD","FHLC","SG9999015978.USD","LU0106261372.USD","MEDX","IE00BJT1NW94.SGD","LU0882574055.USD","SG9999018857.SGD","IE00B4R5TH58.HKD","LU0061475181.USD","LU0058720904.USD","LU0640476718.USD","LU1868836914.USD","LU1804176565.USD","LU2168564149.EUR","IHE","LU2552382058.USD","LU2552382132.HKD","LU0385154629.USD","LU1988902786.USD","LU0353189763.USD","PPH","SGXZ57979304.SGD","LU0266013472.USD","LU0174119429.USD","LU0471298777.SGD","SG9999014898.SGD","IE0009355771.USD","LU1551013342.USD","LU0234572021.USD","GDOC","LU0964807845.USD","LU1061106388.HKD","LU0320765992.SGD","OZEM","LU1989771016.USD","LU0225283273.USD","SG9999014906.USD","LU2471134879.HKD","SG9999001176.SGD","IE00BJLML261.HKD","LU0320765059.SGD","LU2491050154.USD","IE0004445015.USD","LU1323610961.USD","LU0079474960.USD","LU2746668461.USD","SG9999015945.SGD","LU0203202063.USD","LU0210536198.USD","BK4585","LU0109391861.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300583","title":"Amplia Therapeutics - to Begin Study in Late 2026 in Australia and USA","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300583","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300583?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:22","pubTimestamp":1785795752,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUE1KKBYJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656130058","title":"Amplia Therapeutics - and Lilly to Evaluate Narmafotinib and Olomorasib Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2656130058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656130058?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:22","pubTimestamp":1785795752,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUE1KKBYJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656005853","title":"Amplia Therapeutics Ltd-Amplia Signs Collaboration and Supply Agreement with Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=2656005853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656005853?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:22","pubTimestamp":1785795752,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUE1KKBYJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655695173","title":"Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer NOW Online","url":"https://stock-news.laohu8.com/highlight/detail?id=2655695173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655695173?lang=en_us&edition=fundamental","pubTime":"2026-07-31 20:45","pubTimestamp":1785501900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nTUA9KXFDM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649980326","title":"Amplia Announces Appointment of Brett Carter to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2649980326","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649980326?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:45","pubTimestamp":1783428300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUAYLJ41:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649754621","title":"Amplia Therapeutics Names Jane Bell Chair as Warwick Tong Steps Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2649754621","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649754621?lang=en_us&edition=fundamental","pubTime":"2026-07-06 20:45","pubTimestamp":1783341918,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics names Jane Bell chair as Warwick Tong steps downAmplia named Jane Bell AM as board chair effective June 30, 2026, replacing Warwick Tong, who retired from the chair role.Tong will ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL3Tk8yT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK7067","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4585","BK4112","LU2210149790.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","BCDF","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","ATX.AU","SG9999014021.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649564992","title":"Amplia Therapeutics Says Warwick Tong Will Retire as Board Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2649564992","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649564992?lang=en_us&edition=fundamental","pubTime":"2026-07-06 15:15","pubTimestamp":1783322130,"startTime":"0","endTime":"0","summary":"June 30 (Reuters) - Amplia Therapeutics Ltd::*WARWICK TONG WILL RETIRE AS BOARD CHAIRMAN*APPOINTS JANE BELL AM AS BOARD CHAIR EFFECTIVE 30 JUNE 2026*Further company coverage: ATX.AX* ((Reuters.Briefs@","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nRSD7CYpPn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647585275","title":"Amplia Therapeutics Says Warwick Tong Will Retire as Board Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2647585275","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647585275?lang=en_us&edition=fundamental","pubTime":"2026-06-30 09:38","pubTimestamp":1782783522,"startTime":"0","endTime":"0","summary":"BRIEF-Amplia Therapeutics Says Warwick Tong Will Retire As Board ChairmanJune 30 (Reuters)-Amplia Therapeutics LtdATX.AX:WARWICK TONG WILL RETIRE AS BOARD CHAIRMANAPPOINTS JANE BELL AM AS BOARD CHAIR EFFECTIVE 30 JUNE 2026Further company coverage:ATX.AX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN431164:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647589300","title":"Amplia Therapeutics Ltd - Warwick Tong Will Retire as Board Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2647589300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647589300?lang=en_us&edition=fundamental","pubTime":"2026-06-30 06:18","pubTimestamp":1782771519,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nFWN431164:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647130058","title":"Amplia Therapeutics - Appoints Jane Bell am as Board Chair Effective 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647130058","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647130058?lang=en_us&edition=fundamental","pubTime":"2026-06-30 06:18","pubTimestamp":1782771519,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nFWN431164:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646839847","title":"Amplia Therapeutics Says Washington H. Soul Pattinson Becomes Substantial Holder","url":"https://stock-news.laohu8.com/highlight/detail?id=2646839847","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646839847?lang=en_us&edition=fundamental","pubTime":"2026-06-25 08:24","pubTimestamp":1782347063,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  received notice that Washington H. Soul Pattinson  and its subsidiaries became substantial holders of the company on Monday, according to a Thursday Australian bourse filing.Washington H. Soul Pattinson now owns 27.5 million shares in the company, representing a 5.37% total voting power, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SOL.AU","ATX.AU","BK4139","WASH","BK7105","BK4539","BK7083","BK4007","BK4211","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645862591","title":"Amplia Therapeutics Says Pengana Capital Becomes Substantial Holder","url":"https://stock-news.laohu8.com/highlight/detail?id=2645862591","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645862591?lang=en_us&edition=fundamental","pubTime":"2026-06-24 14:09","pubTimestamp":1782281341,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics (ASX:ATX) said Pengana Capital became a substantial holder in the company on June 22 with a stake of 5.37% or 27.5 million shares, according to a Wednesday Australian bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4539","BK4007","BK4139","LENZ","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639645262","title":"Amplia Therapeutics - Loss for Year Attributable a$7.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2639645262","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639645262?lang=en_us&edition=fundamental","pubTime":"2026-05-29 11:40","pubTimestamp":1780026002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nFWN42516N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639452186","title":"Amplia Therapeutics Ltd - FY REV and Other Income a$5.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2639452186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639452186?lang=en_us&edition=fundamental","pubTime":"2026-05-29 11:40","pubTimestamp":1780026002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nFWN42516N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636071300","title":"Amplia Therapeutics to Start Phase 2B Study of Pancreatic Cancer Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2636071300","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636071300?lang=en_us&edition=fundamental","pubTime":"2026-05-19 07:56","pubTimestamp":1779148606,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  is initiating a phase 2b study of its narmafotinib drug candidate in combination with chemotherapies gemcitabine and Abraxane in newly diagnosed advanced pancreatic cancer patients to explore a new dosing regimen, according to a Tuesday Australian bourse filing.Each dosing group will have six patients, which will be combined with gemcitabine and Abraxane given on their conventional schedule, the filing said. The study will assess safety and tolerability, pharmacokinetics, and efficacy. Exploratory endpoints will include effects on disease biomarkers as well as effects on fibrosis.The study, designed in alignment with US Food and Drug Administration feedback, will enroll patients across three to four sites in Australia starting in the fourth quarter, per the filing. It will form the first stage of a registrational study in this indication.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK7067","ATX.AU","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636672002","title":"Amplia Therapeutics launches Phase 2b narmafotinib trial in advanced pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2636672002","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636672002?lang=en_us&edition=fundamental","pubTime":"2026-05-19 06:58","pubTimestamp":1779145129,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics launched the first stage of a Phase 2b pancreatic cancer study of narmafotinib, positioning it as the opening step toward a registration-focused program aligned with FDA feedback.Results from this new study have not been presented yet; initial safety, tolerability, and drug-level readouts are expected in Q2 2027 following enrollment planned to start in Q4 2026.The trial will test a new daily dosing approach for narmafotinib alongside standard chemotherapy, aiming to strengthen the treatment’s overall benefit without adding meaningful burden versus chemotherapy alone.The move builds on earlier ACCENT trial results that have already been presented, which indicated improved outcomes versus chemotherapy alone.Narmafotinib holds FDA orphan drug and fast track designations in pancreatic cancer, supporting the company’s regulatory strategy in a high unmet-need setting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLYlV0c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634603912","title":"Amplia Therapeutics issues 240,385 shares on CMO option exercise under equity plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2634603912","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634603912?lang=en_us&edition=fundamental","pubTime":"2026-05-12 14:53","pubTimestamp":1778568819,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics issued 240,385 fully paid ordinary shares from exercise of Zero Exercise Price Options under its Equity Incentive Plan.New shares will rank pari passu with existing ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplia Therapeutics Ltd. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLjRcY6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}]}}